Podcasts

Dr. Neil Hayward, CEO and founder of eXlthera, is here to discuss his company, which is developing Factor XI inhibitor antithrombotics that are attacking blood clots from a new angle and are giving patients new hope.

George Baxter, CEO of Edinburgh Innovations, is here to discuss the company's commercialization model, and how his group is bringing innovation to market in Scotland.

Jack Khattar, president and CEO of Supernus Pharmaceuticals, talks about his experience bringing ADHD drugs to market in a challenging environment.

Eric Turbiville, author of the recently published book “The Perfect Leadership Triad: How Top Executives Maximize Productivity through People, Coaching, and Performance," a 25-year pharma veteran, credentialed executive coach, and director of mentoring for the Southwest region of the Healthcare Businesswomen’s Association says there are three leadership principles can help executives through tumultuous times.

Kurt Orlofski, CEO of Pharmaceutical Associates Inc., discusses what the pharmaceutical supply chain might look like post COVID-19, and how companies can prepare for that.

Dr. Eric von Hofe, Chief Scientific Officer at NuGenerex Immuno-Oncology talks about the recent outbreak of Wuhan coronavirus around the world and how biotechs and pharma are jumping in to help find a solution.

Pharm Exec speaks with Nigel Breakwell and Ben Randal, co-founders of Dot I/O Health. Nigel and Ben talk about how they’re using data science in the health and life sciences industries to help clients navigate emerging markets.

Pharm Exec editors discuss the themes chosen for the January issue focusing on industry trends for the coming year.

Heather Monte, Director of Operations for DirectRx, talks about the specialty pharma’s new Patient Scorecard, which aims to identify and improve adherence by reporting patients’ prescription patterns to doctors.

Julia Owens, co-founder and CEO of Millendo Therapeutics talks about how to keep a company on the path to success, even when there are bumps in the road. She discusses the value of focusing on strengths and how that is currently working for Millendo in the endocrine space.

William Lewis, chairman and CEO of Insmed talks about the approval of the company’s drug Arikayce through the FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs, some ideas that he spoke about on the recent NORD panel about innovative and ethical partnerships, and Insmed’s pipeline and progress.

Pharm Exec editors discuss the articles they focused on for the November Annual Pipeline Report.

Sven Klingemann, research director at Reputation Institute talks about pharma’s negative public perception and what the industry can do to improve it.

Pharm Exec editors interview Mark Glickman, Chief Commercial Officer of Esperion Therapeutics. Glickman discusses the overall cholesterol-lowering space and how it’s planning to add a new therapeutic option for patients, what it means to establish a new therapy in a statin-dominated market, market research approaches, and more.

Jeannine Lynch, senior director at BioMarin Pharmaceuticals, oversees patient access services and talks with editors about the patient journey in regard to receiving therapies, how to engage with patients more effectively, and where she sees the pharma industry in terms of patient engagement and patient centricity.

Janssen’s company group chairman of Europe, Middle East, and Africa operations, Kris Sterkens speaks with Pharm Exec editors. Kris talks about his finance background, global pricing issues, and challenges and opportunities for EMEA biopharma breaking into the US market.

Apellis’ CEO and co-founder, Dr. Cedric Francois talks with Pharm Exec editors about his journey from clinical work to creating biotech startups, which has included research, clinical work, and the launch of two startups.

Christine Sakdalan, Head of Franchise Strategy and Customer Solutions at Janssen Pharmaceutical talks with Pharm Exec editors about how patient-centricity fuels innovation, the difference between patient and customer centricity, and educational programs that need to be implemented for patients, providers, and payers.

Pharm Exec editors sit down with Mark Velleca, CEO of G1 Therapeutics. In this episode, Mark talks about how he differentiates himself in the oncology field, why he considers G1 Therapeutics an "old school company," and about the North Carolina biotech landscape.

Pharm Exec editors share insights into what they've been working on this summer for the June, July, and August issues; plus a sneak peek into what's coming in September!

Robert Finkel, the CEO of The FreshBlood Group talks with Pharm Exec editors about the positives and negatives of pharma’s marketing needs, the details and evolution around founding The FreshBlood Group, and how emerging pharma and biotech companies can budget in successful marketing.

Cameron Turtle, Chief Business Officer of Eidos Therapeutics, Robin Toft, Founder and CEO of The Toft Group Executive Search and Sabrina Johnson, President and CEO, Daré Bioscience join Pharm Exec editors to talk about the future of the life sciences executive.

Pharm Exec editors speak with Jigar Raythatha, CEO of Constellation Pharmaceuticals. He talks about his roles, the importance of having a Plan B in biotech, creating a translationally enabled company, and how he leads his team at Constellation.

Pharm Exec's European Editor, Julian Upton, speaks with Johnson & Johnson's Jennifer Turgiss, VP Behavior Science & Advanced Analytics group. In their interview, Turgiss discusses behavioral strategies to the health and wellness solutions being developed at J&J.

Editor-in-Chief Lisa Henderson speaks with Bill Newell, CEO of Sutro Bipharma about his background in corporate law and how it helps him in his role as a biotech executive, the importance of collaboration between big pharma and biotech, a story about keeping the San Francisco Giants in the Bay area, and other analogies around sports related to running a biotech.

Pharm Exec editors interview Anna Sundgren, the renal disease strategy leader, Global Medicines Development at AstraZeneca, about the current CVRM landscape, challenges to renal drug development, and new therapeutics for chronic kidney disease.